Salvage therapy for children with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
2017
Background In the tyrosine kinase inhibitor (TKI) era, outcomes after
salvage therapyfor relapsed or refractory
Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) remain unclear. Procedure The clinical courses of 19 patients with relapse (n = 13) or induction failure (n = 6) in the Japanese Pediatric Leukemia/Lymphoma Study Group Ph+ ALL04 study were retrospectively reviewed. Results Fifteen male and four female patients had a median age of 8 (range 4–15) years at relapse or induction failure. Patients received
imatinibin combination with
hyperfractionatedcyclophosphamide, vincristine, doxorubicin, and dexamethasone (
hyper-CVAD) and methotrexate and
cytarabine(MTX/Ara-C) (n = 9),
imatinibin combination with other chemotherapy (n = 5), chemotherapy without
imatinib(n = 2),
imatinibalone (n = 2), or no additional chemotherapy (n = 1). Two patients underwent hematopoietic stem cell transplantation (HSCT) without achieving complete remission (CR) and died of leukemia. The remaining 17 patients achieved CR with
salvage therapiesand underwent HSCT whilst in CR: 10 patients remain alive in CR, five died of transplantation-related complications, and two died of relapse. In six of seven patients with available data on
minimal residual disease(MRD),
imatinibin combination with the first course of
hyper-CVADwas more effective in achieving a favorable MRD response compared with the Ph+ ALL04 induction regimen. Conclusion This study suggested that
cross-resistanceto
imatinibfailed to develop after conventional chemotherapy.
Imatinibin combination with chemotherapy including
hyper-CVAD+MTX/Ara-C was effective and safe for relapsed or refractory Ph+ ALL patients who received frontline therapy without
imatinib.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
13
References
3
Citations
NaN
KQI